I am pretty irritated as well. The one thing I have learned about investing in biotech is that you can have incredible science, but if your management is not good as well, you might as well just throw your money out the window. I am not selling down here, but this makes me think a whole lot less of Marker’s management. It is not rocket science to get an abstract accepted for ASCO. What else might they screw up in the future? This makes me wary....